Glipizide is a hypoglycemic drug of the sulfonylureas family that is prescribed to treat type II diabetes. Glipizide stimulates insulin excretion by ß-pancreatic cells.
Hypersensitivity, type 1 diabetes mellitus; diabetic cetoacidosis; diabetic coma.
Risk of hypoglycaemia that could cause coma; symptoms of hypoglycaemia that are difficult to recognize in the elderly and treatment with beta-adrenergics.
Precautions should be taken in patients with: liver failure and renal failure, the elderly, debilitated or malnourished patients, patients with adrenal or pituitary insufficiency, trauma patients.
Caution should be exercised with the intake of glipizide during surgical interventions, infectious and febrile diseases, patients with glucose-6-phosphate dehydrogenase deficiency (due to risk of hemolytic anemia), concomitant treatment with antifungals.
The adjustment of the dose of glipizide should be assessed together with adherence to diet and exercise. Monitorization of glucose levels and glycosylated hemoglobin is highly recommended.
Safety / efficacy in children has not been established.
Hypoglycaemia, nausea, diarrhea, pain in the upper part of the abdomen, abdominal pain.
Glipizide increases its hypoglycemic effect if taken together with: alcohol, antifungals (miconazole, fluconazole, voriconazole), NSAIDs, salicylates, ß-blocking agents, ACEI (angiotensin-converting enzyme inhibitors), H2-receptor antagonists, antacids , MAOIs, fluoroquinolones.
Glipizide decreases its hypoglycaemic effect and may exist hyperglycemia risk if taken in concomitancy with: phenothiazines, corticosteroids, sympathomimetics, thiazide diuretics and other diuretics, treatments for the control of thyroid function, oral contraceptives, estrogens and progestogens, phenytoin, nicotinic acid , isoniazid and calcium channel blockers.
- Minodiab ®
Gene or region studied